Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May:59:101040.
doi: 10.1016/j.blre.2023.101040. Epub 2023 Jan 20.

State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease

Affiliations
Free article
Review

State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease

Alice Sabinot et al. Blood Rev. 2023 May.
Free article

Abstract

Amyloidosis is the term to define a broad array of rare protein misfolding syndromes. Among them, light chain (AL) amyloidosis is the most common, affecting roughly 10 people per million/year. The core purpose of the present literature review is to shed light on the academic and clinical knowledge on the condition, encompassing its i) epidemiology, ii) economic burden, and iii) quality of life consequences. The areas of interest are Europe and North America. Literature search was primarily performed on Embase® and finally integrated with additional, deemed eligible, sources. Pre-defined PICOS criteria were employed for the inclusion and exclusion processes. A total of 64 studies were comprehensively included in the current literature review as compliant with the inclusion criteria. The results were presented according to the outcomes of interest and eventually triangulated and compared to available literature studies. A broad picture on the main aspects of AL amyloidosis is delivered.

Keywords: AL amyloidosis; Epidemiology; Light-chain amyloidosis; PRISMA guidelines; Risk-staging; Systematic literature review.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest AS and GG are employees of AdRes s.r.l., which have received project funding by Janssen for the development of this review. LP is partner and employee of AdRes s.r.l., which has received project funding by Janssen for the development of this research. SB and AL are employees of Janssen. GP is full professor of clinical chemistry at University of Pavia, his competing interests are: Alexion (Advisory board, honoraria), Argobio (Advisory board, honoraria), Janssen (Advisory board, honoraria), Protego (Advisory board, honoraria), Gate bioscience (Research funding), The Binding Site (Research funding, honoraria), Pfizer (Honoraria), Prothena (Honoraria), Sebia (Honoraria), Siemens (Honoraria).

Similar articles

Cited by

MeSH terms

LinkOut - more resources